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Abstract
Purpose Obesity and breast density are both associated with
an increased risk of breast cancer and are potentially modifi-
able. Weight loss surgery (WLS) causes a significant reduc-
tion in the amount of body fat and a decrease in breast cancer
risk. The effect of WLS on breast density and its components
has not been documented. Here, we analyze the impact of
WLS on volumetric breast density (VBD) and on each of its
components (fibroglandular volume and breast volume) by
using three-dimensional methods.
Materials and Methods Fibroglandular volume, breast vol-
ume, and their ratio, the VBD, were calculated from mammo-
grams before and after WLS by using Volpara™ automated
software.
Results For the 80 women included, average body mass index
decreased from 46.0 ± 7.22 to 33.7 ± 7.06 kg/m2.
Mammograms were performed on average 11.6 ± 9.4 months
before and 10.1 ± 7 months after WLS. There was a significant
reduction in average breast volume (39.4 % decrease) and aver-
age fibroglandular volume (15.5 % decrease), and thus, the av-
erage VBD increased from 5.15 to 7.87 % (p < 1 × 10−9) after
WLS. When stratified by menopausal status and diabetic status,
VBD increased significantly in all groups but only perimeno-
pausal and postmenopausal women and non-diabetics experi-
enced a significant reduction in fibroglandular volume.
Conclusions Breast volume and fibroglandular volume
decreased, and VBD increased following WLS, with
the most significant change observed in postmenopausal
women and non-diabetics. Further studies are warranted
to determine how physical and biological alterations in
breast density components after WLS may impact breast
cancer risk.
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Introduction
Mammographic density is a term used to describe the propor-
tion of radiopaque, fibroglandular/dense tissue on a mammo-
gram. Over the last few decades, there has been increasing
attention to the association between mammographic density
and the risk of breast cancer development. In 1976, Wolfe first
reported that breast cancer risk was associated with mammo-
graphic parenchymal patterns [1]. Although initially this in-
creased risk was attributed to a Bmasking bias^ stemming
from difficulty in detecting a tumor against a radiodense back-
ground, further studies confirmed that a higher density in and
of itself conferred additional risk [2]. Multiple studies have
consistently shown a twofold to sixfold increased risk of
breast cancer in women with the highest measures of mam-
mographic density compared to the lowest [3, 4]. It is becom-
ing evident that density is a dynamic phenotype of processes
occurring in the body and is influenced by many factors in-
cluding age, menopausal status, parity, hormonal changes,
body mass index (BMI), and metabolic changes [5–8].
Several studies have now shown that reductions in mammo-
graphic density over time, for example, in response to endo-
crine therapies, are associated with a significant decrease in
breast cancer risk [9–15]. Because density is a modifiable risk
factor and can be targeted for cancer risk reduction, there is a
great deal of interest in investigating the biologic and molec-
ular mechanisms that link breast density to breast cancer risk.
The increased absolute risk of postmenopausal breast cancer
with increasing BMI is well known, although the reason for this
association is not clear [16]. Large epidemiologic studies have
shown that weight loss surgeries (WLS), like Roux-en-Y gastric
bypass, reduce the risk of postmenopausal breast cancer [17–20].
Weight loss surgery not only results in a drastic reduction in BMI
but also often reverses diabetes and many components of the
metabolic syndrome [21, 22]. Metabolic syndrome and insulin
resistance are associated with mammographic dense breasts [23].
In most patients, WLS causes a significant reduction in body fat,
which is expected to increase breast density due to the inverse
relationship of mammographic density with BMI [24]. Yet, par-
adoxically, a decrease in breast cancer risk in fact occurs after
WLS. There have been no published studies reporting the impact
of WLS on breast density and whether both components that
comprise density, i.e., the fibroglandular tissue and the adipose
tissue, are affected. WLS is likely to change both these compo-
nents that make up density, due to changes in growth factors and
hormones such as insulin-like growth factor-1 (IGF-1), and es-
trogen levels after surgery [25–27]. With improvements in met-
abolic regulation after WLS, changes in the fibroglandular
compartment of the breast may also significantly contribute to
the reduction in breast cancer risk.
Clinically, the most widely used method for assessing mam-
mographic density is the Breast Imaging Reporting and Data
System (BI-RADS) composition categories, a subjective mea-
sure of the extent to which the amount of dense tissue in the
breast could potentially obscure small lesions [28]. BI-RADS
density categories are fairly broad (∼80 % of women fall into
the middle two categories) and may not be sensitive enough to
detect clinically meaningful changes in mammographic density
[29]. Most of the recent epidemiological studies investigating
mammographic density and breast cancer risk have chosen to
use quantitative visual assessments or semi-automated or fully
automated methods for quantifying breast density. However, one
study looking at mammographic density reduction after tamoxi-
fen by Cuzick et al. noted that the minimum change that could
reproducibly be detected by using a quantitative visual mammo-
graphic density scale was 10 % [10].
Recent advances in quantifying mammographic density by
using volumetric methods have several advantages over visual
and two-dimensional area-based measures. Volumetric methods
capture information that represents the three-dimensional nature
of breast tissue. Highly correlated to ground truth measurements
from MRI, volumetric methods show good reliability across se-
rial mammograms and are significant predictors of breast cancer
risk [30–36]. Commercial volumetric methods can also output a
volumetric density grade analogous to the BI-RADS categories
and have been validated compared to visual assessment [37–40].
In the present single-institution retrospective study, using
volumetric density measures, we analyzed the impact of WLS
on breast density and on each of the components that deter-
mine breast density.
Methods
This study is a retrospective analysis to determine the change in
breast density measured from full-field digital mammography
images by using the Volpara method (Algorithm version 1.4,
Volpara Solutions, Wellington, New Zealand) in women under-
goingWLS. The studywas approved by the Institutional Review
Board at East Carolina University and was in compliance with
the Health Information Portability and Accountability Act.
Subjects All patients who underwent WLS from 2003 to
2013 at Vidant Medical Center by bariatric surgeons at The
Brody School of Medicine, East Carolina University in
Greenville, North Carolina, were identified. As shown in
Fig. 1, a total of 1848 patients either underwent a gastric bypass,
gastric banding, or sleeve gastrectomy. All men (n = 327), pa-
tients without any mammographic data (n = 1157), patients with
only one mammogram (n = 144), and patients without both a
preoperative and postoperative mammogram (n = 90) were
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excluded. Of the 130 patients who met the inclusion criteria, 43
patients were excluded because raw processing mammographic
data were not available. An additional seven patients were ex-
cluded because the only preoperative or postoperative mammo-
gram available was a unilateral mammogram. Eighty patients
had the necessary radiologic data to be included in the study.
Assessment of Volumetric Breast Density Using Volpara™
Volpara™, previously described by Aitken et al., is an FDA-
cleared, fully automated software used for estimating volu-
metric breast density [41, 42]. Volpara™ analyzes digital
mammographic data in a volumetric fashion and produces a
quantitative assessment of breast composition by using
fibroglandular volume (FGV), total breast volume, and their
ratio to determine volumetric breast density (VBD). Pre-WLS
and post-WLS mammograms were identified for each patient.
When multiple presurgery mammograms were available, the
images captured closest to the surgery date were used for
density measurements. For the postoperative mammogram,
the first mammogram that was acquired at least 60 days after
surgery was used. Raw mammographic data for craniocaudal
and mediolateral oblique views of preoperative and postoper-
ative bilateral screening mammograms performed at a single
breast imaging center were obtained to calculate average
compressed breast thickness, total breast volume, FGV, and
VBD by using the Volpara imaging software. Using preset
thresholds of VBD, Volpara also outputs a Volpara density
grade (VDG) corresponding to the BI-RADS density catego-
ries (i.e., VDG 1VBD<4.5%, VDG 2VBD ≥4.5 and <7.5%,
VDG 3 VBD ≥7.5 and ≤15.5 %, VDG 4 VBD >15.5 %)
which are also reported in the analysis.
For women who did not have menopausal status clearly
documented in the medical record (n = 38), age <45 years
was considered premenopausal, between 45 and 55 years as
perimenopausal, and >55 years as postmenopausal. Women
who changed menopausal status during the study period were
included in the perimenopausal group.
Statistical Analysis Changes in breast density and other
numeric variables were analyzed by using the one-
sample t test with 95 % confidence intervals for the mean
change. Box plots revealed a few moderate outliers for
some of the variables, but we found no indications of
any gross violations of the analyses based on the t test.
In some cases, the tests were repeated on the log scale
with no changes in statistical significance at the 5 % level.
The postsurgery measurements were taken between 2 and
40 months after surgery; however, scatter plots of the
Fig. 1 Study population
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changes plotted against the time of measurement did not
show an important trend. These analyses were repeated on
subgroups defined by menopausal status, diabetes status,
and race. Change in VBD for patients having both pre-
WLS and post-WLS BI-RADS density scores of 2 was
also independently analyzed. Analyses were performed
by using RStudio (version 0.98.501, Boston, MA,
http://www.rstudio.com) and R (version 3.0.2 with the
mosaic package, http://www.R-project.org/).
Results
Characteristics of the Study Population
As shown in Fig. 1, 80 patients had the necessary radio-
logic data to be included in the study. Table 1 highlights
the characteristics of the study population, and Table 2
compares relevant patient variables at the time of their
pre-WLS and post-WLS mammogram. The mean BMI at
the t ime of the preopera t ive mammogram was
46.0 ± 7.22 kg/m2; this decreased to 33.7 ± 7.1 kg/m2 at
the time of the postoperative mammogram. The most
common WLS was a laparoscopic gastric bypass with
62 (78 %) patients undergoing it. The other types of
WLS performed included open gastric bypass, laparo-
scopic sleeve gastrectomy, and gastric banding. Through
the study period, 16 (20 %) women were premenopausal,
27 (33.8 %) were perimenopausal, and 37 (46.2 %) were
postmenopausal. The preoperative mammogram was per-
formed on an average of 11.6 ± 9.4 months prior to
weight loss surgery. On average, the postoperative mam-
mogram was performed 10.1 ± 7.0 months post-WLS; this
time interval ranged from 2 to 40 months. Thirty-five
(44 %) patients had type II diabetes mellitus prior to sur-
gery. Resolution of diabetes was observed in 21 (60 %) of
these patients after surgery.
Total Breast Volume and Compressed Breast Thickness
Decrease After Weight Loss Surgery
In the entire study population, the total breast volume de-
creased an average of 579.7 ± 444 cm3 from 1469.89 to
890.17 cm3 (a significant 39.4 % decrease, p < 2.2e-16).
Both adipose volume and FGV make up the total breast vol-
ume. This extreme reduction in the total breast volume is
consistent with the significant weight loss and decrease in
BMI in these patients. The average decrease in compressed
breast thickness was 22.36 ± 12.67 mm (p < 2.2e-16) from
67.56 to 45.20 mm. This trend in reduction of total breast
volume and compressed breast thickness was observed in
women regardless of menopausal status.
Fibroglandular Volume Decreases After Weight Loss
Surgery
The mean FGV on the preoperative and postoperative mam-
mograms was 70.5 ± 30.6 and 59.6 ± 27.64 cm3, respectively,
with an average decrease of 15.5 % (p = 0.0004, 95 % CI
−16.78, −5.03) as shown in Fig. 2, top panel a.When stratified
by menopausal status (Fig. 2, top panel b, c, d), the premen-
opausal group had an average decrease in FGV of
5.9 ± 30.9 cm3, but this change was not statistically significant
(p = 0.46). However, both the larger perimenopausal (n = 27)
and postmenopausal (n = 37) cohorts had a greater and signif-
icant decrease in FGV of 13.1 ± 28.2 cm3 (p = 0.02) and
11.5 ± 23.3 cm3 (p = 0.005), respectively. The average times
to mammogram for the perimenopausal and postmenopausal
groups were 11 ± 8.1 and 9 ± 6.5 months after WLS, respec-
tively. Adipose volume was calculated as the difference in the
total breast volume and FGV. As expected after WLS, adipose
volume decreased significantly in all groups (data not shown).
The mean adipose volume for the entire population before and
after surgery was 1399.41 ± 577.7 and 830.6 ± 475.17 cm3,
with the mean decrease in the total adipose volume being
568.82 ± 431.19 cm3 (p < 1 × 10−15).
Table 1 Characteristics
of the women in the
study
Variable N (%)
Race
White 44 (55)
African American 36 (45)
History of contraceptive use
No 69 (86.3)
Yes 11 (13.8)
Hormone replacement therapy
No 68 (85.0)
Yes 12 (15.0)
Family history of breast cancer
No 41 (51.3)
Yes 39 (48.8)
Alcohol use
No 72 (90.0)
Yes 3 (3.8)
Unknown 5 (6.2)
Smoking history
Never 51 (63.8)
Former 23 (28.7)
Active 6 (7.5)
Weight loss surgery
Lap gastric bypass 62 (77.5)
Lap sleeve gastrectomy 8 (10.0)
Lap gastric band 7 (8.8)
Open gastric bypass 3 (3.7)
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Volumetric Breast Density Increases After Weight Loss
Surgery Regardless of Menopausal Status
For the entire study population, the mean percent VBD prior
to undergoing WLS was 5.2 ± 2.04 % (range, 2.1 to 13.4 %)
and increased to 7.9 ± 3.90 % (range, 2.6 to 21.1 %) after
WLS (p < 0.0001). The increase in VBD was significant re-
gardless of the menopausal status (Fig. 2, lower panel).
In the 16 patients who were premenopausal prior to surgery
and remained premenopausal at the time of follow-up mam-
mogram, average breast density increased by 3.8 %, from 4.9
to 8.7 % (p = 0.003). Twenty-seven patients in the perimeno-
pausal group also had an increase in breast density with an
average increase in density from 5.3 ± 1.69 to 8.20 ± 4.20 %
(p = 0.0004). The 37 individuals who were postmenopausal
prior to WLS also had a significant increase in breast density
from 5.2 to 7.2 % (p < 0.0001).
Volumetric Breast Density Increases Regardless
of Diabetic Status, but only Non-Diabetics Experience
a Significant Decrease in Fibroglandular Volume
Prior to the operation, 35 patients (44 %) had type 2 diabetes
mellitus, nine of whom were on insulin. At the time of their
postoperative mammogram, 14 (18%) had diabetes, with only
4 taking insulin. Twenty-one patients (60 % of diabetics) had
resolution of their diabetes postoperatively. Regardless of the
diabetic status, there was a significant increase in breast den-
sity as shown in Fig. 3, lower panel. As shown in Fig. 3, upper
panel, non-diabetics (n = 45) prior to surgery had a significant
mean reduction in FGVof 14.6 cm3 (p = 0.001). Similarly, 21
patients who had resolution of their diabetes also had a reduc-
tion in FGV of 10.6 cm3 (p = 0.08). In contrast, the FGV of
those patients who remained diabetic at the time of their post-
operative mammogram was not significantly different (0.4-
Table 2 A comparison of
characteristics of the study
population at the time of the pre-
weight and post-weight loss
surgery mammograms
Variable Pre-WLS
mammogram
N (%)
Post-WLS
mammogram
N (%)
p value
Total 80 80
Age (years)
Mean ± SD 51.4 ± 7.70 53.2 ± 7.46 0.13
Median (range) 51.4 (35.8–67.0) 53.4 (38.2–68.4)
BMI (kg/m2)
Mean ± SD 46.0 ± 7.22 33.7 ± 7.06 <0.0001
Median (range) 44.4 (35.1–68.2) 33.5 (18.5–54.3)
Diabetes
Yes 35 (43.8) 14 (17.5) 0.002
No 45 (56.2) 66 (82.5)
Insulin use
Yes 10 (12.5) 4 (5.0) 0.09
No 70 (87.5) 76 (95.0)
BI-RADS scorea
0 2 (2.8) 1 (1.3) 0.62
1 39 (54.9) 41 (53.2)
2 30 (42.3) 34 (44.2)
4c 0 1 (1.3)
BI-RADS densitya
1 Almost entirely fat 4 (5.6) 7 (9.1) 0.43
2 Scattered fibroglandular densities 52 (73.2) 49 (63.6)
3 Heterogeneously dense 15 (21.1) 20 (26.0)
4 Extremely dense 0 1 (1.3)
Type of mammogram
Screening 59 (73.8) 70 (87.5) 0.002
Diagnostic 13 (16.2) 10 (12.5)
Unknown 8 (10.0) 0
a Information not available on all participants
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cm3 mean increase; p = 0.94). There was no significant differ-
ence in the timing of the postoperative mammograms; non-
diabetics underwent a postoperative mammogram on average
9.5 ± 6.4 months from surgery compared to the diabetic group
who underwent mammogram 10.9 ± 7.8 months after surgery
(p = 0.42).
Volumetric Breast Density Increased and Fibroglandular
Volume Decreased Regardless of Race
Both white and African American women, who were well
represented in the study, had a significant increase in breast
density afterWLS (p < 0.0001 for the entire study population).
African American women had a 13.3-cm3 reduction in FGV
(p = 0.005), and white women had a 9.0-cm3 reduction in
FGV (p = 0.03). A statistically significant difference was not
observed in the amount of reduction in FGV between African
American and white women.
Change in BI-RADS Density Score After Weight Loss
Surgery
We analyzed change in BI-RADS density pre and post WLS.
The BI-RADS 2 (scattered fibroglandular density) density
category was the most common both preoperatively and
postoperatively (52 and 49 patients, respectively), followed
by BI-RADS 3 (heterogeneously dense; 15 and 20 patients,
respectively) (Table 3). Nine patients did not have a BI-RADS
density score available for the preoperative and/or the postop-
erative mammogram. There was no important change evident
in BI-RADS density scores after WLS; pre-WLS and post-
WLS BI-RADS scores remained the same for 45 of the 80
patients, increased by 1 in 12 patients, increased by 2 in 1
patient, and decreased by 1 in 13 patients.
BI-RADS Density Versus Volumetric Breast Density
The distribution of patients into Volpara density grades based
on the VBD both pre-WLS and post-WLS is shown in Fig. 4a.
The majority of mammograms before WLS were either
VDG1 (n = 35 or 44 %) or VDG2 (n = 37 or 46 %) with none
in VDG4, the most dense category (VBD > 15.5 %).
However, this profile shifted dramatically to higher VDGs
after WLS: 11 VDG1, 39 VDG2, 26 VDG3, and 4 VDG4.
The average VBD of all of the patients with a BI-RADS
density of 2 (scattered fibroglandular densities) on their pre-
operative mammogramwas 4.8%, while the average VBD for
all of the patients with a BI-RADS density of 2 on the post-
operative mammogram was 7.0 %. Patients with a BI-RADS
density of 3 (heterogeneously dense) on the preoperative
Mean cm3 Δ ± SD
(CI) p-value
-13.1 ±  28.22
(-24.27, -1.94) 0.02
Mean cm3 Δ ± SD
(CI) p-value
-5.91 ± 30.89
(-22.37, -10.55) 0.46
Mean cm3 Δ ± SD
(CI) p-value
-10.91 ± 26.42
(-16.79, -5.03) 0.0004
Mean cm3 Δ ± SD
(CI) p-value
-11.46 ±  23.32
(-19.24, -3.69) 0.005
Mean % Δ ±SD
(CI) p-value
2.71  ± 3.34
(1.97, 3.45) <0.0001
Mean % Δ ± SD
(CI) p-value
3.84 ± 4.39
(1.50, 6.18) 0.003
Mean % Δ ± SD
(CI) p-value
2.94  ± 3.76
(1.45, 4.43) 0.0004
Mean % Δ ± SD
(CI) p-value
2.05  ± 2.26
(1.30, 2.81) <0.0001
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Fig. 2 Difference in fibroglandular volume (FGV, top panel) and
volumetric breast density (VBD, bottom panel) before and after weight
loss surgery in the a entire study population, b premenopausal women, c
perimenopausal women, and d postmenopausal women. N number of
patients in each group. Bold line within the box plot indicates median
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mammogram had an average VBD of 5.9 %, while patients
with a BI-RADS 3 postoperatively had an average VBD of
10.7 %.
To further compare BI-RADS density to VBD, Fig. 4b
graphs the Volpara-calculated VBD of the 36 patient subsets
who had both a preoperative and postoperative BI-RADS
score of 2. The average VBD was 5.16 % on the pre-WLS
mammograms and 7.87 % on the post-WLS mammogram
with a mean difference of 1.91 ± 2.25 % (p < 0.00001, 95 %
CI, 1.16, 2.68). As indicated by the brackets, multiple volume
Mean % Δ ± SD
(CI) p-value
2.96 ± 3.77
(1.83, 4.10) <0.0001
Mean cm3 Δ ± SD
(CI) p-value
-10.58 ± 26.15
(-22.48, 1.33) 0.08
Mean cm3 Δ ± SD
(CI) p-value
-14.58 ± 27.64
(-22.88 ,-6.27) 0.001
Mean % Δ ± SD
(CI) p-value
2.41 ± 2.69
(1.18, 3.64) 0.0006
Mean % Δ ± SD
(CI) p-value
2.34 ± 2.78
(0.74, 3.95) 0.008
Mean cm3 Δ ± SD
(CI) p-value
0.40 ± 20.47
(-11.42, 12.22) 0.94
a
Non-Diabetic
(n=45)
b 
Diabetic Non-Diabetic
(n=21)
c
Diabetic Diabetic
(n=14)
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Fig. 3 Difference in fibroglandular volume (FGV, top panel) and
volumetric breast density (VBD, bottom panel) before and after weight
loss surgery in a non-diabetics, b diabetics who became non-diabetics,
and c diabetics who stayed diabetic. N number of patients in each group.
Bold line within the box plot indicates median
Table 3 BI-RADS density score
pre and post weight loss surgery Post
BI-RADS 1 BI-RADS 2 BI-RADS 3 BI-RADS 4 Unknown Total
Pre BI-RADS 1 0 4 0 0 0 4
BI-RADS 2 7 36 8 1 0 52
BI-RADS 3 0 6 9 0 0 15
BI-RADS 4 0 0 0 0 0 0
Unknown 0 3 3 0 3 9
Total 7 49 20 1 3 80
Bold boxes indicate the number of patients with the same BI-RADS density scores pre and post WLS
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density groups (VDGs) are contained within the BI-RADS
score of 2. After WLS, the VBD increased to include VDG3.
Average FGV however was lower on the postoperative mam-
mograms compared to the preoperative mammograms for the
same BI-RADS score although not statistically significant (data
not shown). For a BI-RADS 2 density, the average FGV preop-
eratively was 67.89 cm3 and postoperatively was 56.9cm3. For
BI-RADS 3 density, the average FGV was 75.01 and 70.68 cm3
preoperatively and postoperatively, respectively.
Discussion
Population studies examining the relationship of BMI and
area density measures focus on the obvious contribution of
adipose tissue in lowering density but do not take into account
how changes in the breast adipose tissue may influence the
fibroglandular tissue due to other factors, for example, hor-
monal changes. With improvements in metabolic regulation
after WLS, both physical and biologic changes in the
fibroglandular compartment of the breast may also significant-
ly contribute to the reduction in breast cancer risk.
Weight loss surgery has a beneficial effect on obesity, dia-
betes, hypertension, and the risk for many cancers including
postmenopausal breast cancer [43]. The impact of WLS on
breast density, itself a significant risk factor for breast cancer,
as a potential mechanism for this reduction in breast cancer
risk, is unknown. We sought to determine the effect of WLS
onVBD and FGVinAfrican American and white obese wom-
en. We observed that obese women undergoing WLS had a
significant increase in percent VBD following the procedure.
This finding does not seem unexpected as adiposity and den-
sity are inversely associated with one another [5].
While there are no studies reporting changes in mammo-
graphic density in women undergoing WLS, a randomized
control trial by Woolcott and colleagues identified no signifi-
cant change in mammographic density at 1 year in women
participating in aerobic exercise versus sedentary women, de-
spite changes in body fat [44]. Our findings are in contrast to
this study. This difference in results may be due to the use of a
more sensitive measurement tool. Different findings may also
be due to the modest change in BMI after exercise versus the
drastic drop in BMI after WLS and the likelihood that weight
loss through exercise and bariatric surgery may have different
effects on breast density. In addition, most subjects in our
study were much more obese with an average BMI of 47
(extremely obese, obesity class III) and a postsurgery average
BMI of 32 (obesity class I), compared to the average BMI of
29 for the study population in the Woolcott study.
Because studies have reported that both absolute dense area
and dense volume are associated with breast cancer risk, we
hypothesized that WLS results in a decrease in FGV (dense
volume) which may contribute to the decrease in breast cancer
risk in this group. We observed a small but significant de-
crease in FGV following WLS in the entire study population
as well as in the subset of postmenopausal women. Both FGV
and percent FGV have been described to be more accurate
predictors of breast cancer risk than percent dense area [45].
In the study by Shepherd et al., the use of FGV significantly
increased risk classification for women with and without
breast cancer [45]. Therefore, the decrease in FGV following
WLS observed in our study may in fact confer a reduction in
breast cancer risk. Failure to observe a decrease in VBD is
related to the massive decrease in fat and total breast volume
compared to the modest decrease in FGV. VBD in this study is
calculated by using Volpara, a software that uses the ratio of
total fibroglandular volume and total breast volume thus ac-
counting for the breast thickness. This not only allows exam-
ination of the relationship ofWLS to density but also provides
measures like FGVwhich reflect the entire dense volume. In a
recent report, the variability in repeated measurement of den-
sity was evaluated for several automated breast density mea-
surement tools, with Volpara being validated the most reliable
making it ideally suited to measure changes in density [30].
While our study does not establish that a reduction in FGV
is what imparts the protective effect, it certainly raises the
possibility that this may be a potential mechanism that should
Fig. 4 a Matrix showing Volpara density grades (VDG) pre and post
weight loss surgery. Shaded bold boxes indicate the number of patients
with unchanged VDG pre and post weight loss surgery. b Volumetric
breast density (VBD) pre and post weight loss surgery in patients who
had an unchanged BI-RADS density score of 2 for the pre and post
weight loss surgery mammogram
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be investigated further. Adipose tissue is known to produce
hormones like estrogen and inflammatory cytokines which
may directly affect proliferation of the adjacent epithelial tis-
sue in the breast [46]. A drastic decrease in the adipose tissue
may have the potential to cause a change in the FGVas early
as a few months after surgery. In fact, in our study population,
a decrease in FGV was seen even in patients who had a mam-
mogram only a few months after surgery. Study results from a
recently completed prospective clinical trial, examining the
effect of weight loss surgery on breast density by using digital
mammography and MRI in women who are at increased risk
for breast cancer, may provide validation of our findings [47]
Another interesting findingwas the lack of change in FGVin
patients who remained diabetic after WLS. Although the sam-
ple size is too small to make definitive conclusions, one possi-
ble explanation for this observation may be related to the pro-
liferative role of the IGF-1 axis on breast epithelium [26, 48].
Our findings thus support future studies to investigate the bio-
chemical changes in the breast tissue before and after WLS.
We report that both premenopausal and postmenopausal
women had a decrease in FGV; however, only postmenopaus-
al women experienced a statistically significant decrease in
FGV. This difference in the change in FGV pre and post bar-
iatric surgery may reflect the difference in biochemical pro-
cesses between premenopausal and postmenopausal women,
as well as a difference in biological effects ofWLS in premen-
opausal and postmenopausal women. Another possibility is
that changes in FGV may have failed to achieve significance
because of the small sample size in the premenopausal and
perimenopausal group.
There are inherent limitations to this study due its retro-
spective nature. Although volumetric density measurements
by using Volpara are fully automated and do not rely on sub-
jective reader evaluations, they can be affected by compres-
sion paddle tilt and mammographic technique, especially with
obese individuals where the effect of paddle tilt is greater [49].
In addition, current mammographic breast compression poli-
cies do not require pressure standardization which may lead to
variation in serial studies [50]. With massive weight loss, the
breast thickness in a given patient changes significantly so that
this problem may be less of an issue once the patient is leaner
but may affect comparisons between presurgery and
postsurgery measurements. As with any chart review, infor-
mation on breast cancer risk factors and other confounding
factors was not reliably available on all patients.
The timing of preoperative and postoperative mammogram
in relation to the WLS varied; therefore, some patients had
their first and only available postoperative mammogram at
60 days, while others did not have one until 3 years. Since
the median time tomammogram from surgery was 10months,
it is unlikely that the significant decrease in FGVobserved in
postmenopausal women in this study is only a result of the
normal aging process. It is well known that the majority of
weight loss occurs within 6–9 months after bariatric surgery.
Because somemammograms were performed before maximal
weight loss was achieved, our results likely underestimate the
changes measured.
To our knowledge, this is the first published study of its
kind to document changes in volumetric breast density and
fibroglandular volume following WLS in a unique population
of patients. The observations in this study are provocative and
warrant a prospective study. Investigations examining the ef-
fect of weight loss on breast and stromal tissue may help
understand the factors that influence breast cancer risk and
provide opportunities for breast cancer prevention.
Conclusions
Obese women who undergoWLS experience many beneficial
health effects, including a reduction in the risk of breast can-
cer. The mechanism for this is unclear; however, given the
various associations between BMI and breast cancer, breast
density and breast cancer, and BMI and breast density, we
sought to determine howWLS impacts not only breast density
but each of the components that comprise density. In this
study, through analysis of mammograms by using automated
volumetric measurements, we show that fibroglandular vol-
ume decreases and volumetric breast density increases follow-
ing weight loss surgery, with the most significant change ob-
served in postmenopausal women and non-diabetics.
Reduction in breast cancer risk following weight loss surgery
may thus be due to an effect on fibroglandular volume but not
volumetric breast density, and a prospective study to evaluate
this hypothesis further is underway.
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